Company profile

OUTLOOK THERAPEUTICS, INC.

NASDAQ:OTLKBiotechnology: Biological Products (No Diagnostic Substances)

Drug pipeline (2)

Asset	Stage	Revenue	Trials	Status
BEVACIZUMAB	phase4	—	16	active
LYTENAVA	approved	$-0.1MQ3 2025	0	—

Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.

Clinical trials (5)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT06190093	phase3	completed	2024-01-24	2024-11-07	Outlook Therapeutics, Inc.	A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT04516278	phase3	completed	2020-10-01	2021-02-10	Outlook Therapeutics, Inc.	A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
NCT05112861	phase3	active_not_recruiting	2021-11-15	2027-12-01	Outlook Therapeutics, Inc.	A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
NCT03844074	phase3	completed	2018-10-01	2020-07-23	Outlook Therapeutics, Inc.	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753	phase3	completed	2019-06-25	2021-06-07	Outlook Therapeutics, Inc.	A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)

FDA applications (1)

Application

Approved

Type

Applicant

Products

BLA 761320

2026-07-24

BLA

OUTLOOK THERAPEUTICS, INC.